Jiwon Yang

Jiwon Yang

Auto-generated profile, based on publicly available information

Jiwon Yang

Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2025 in Gut and Liver
Verified
Journal Article
Open access
PDF file
JYJiwon Yang
Jiwon Yang
YKYe Rim Kim
Ye Rim Kim
SNSeong Kyun Na
Seong Kyun Na
SKSeon-Ok Kim
Seon-Ok Kim
JAJihyun An
Jihyun An
JSJu Hyun Shim
Ju Hyun Shim
Jiwon Yang, Ye Rim Kim, Seong Kyun Na, Seonok Kim, Jihyun An, Ju Hyun Shim. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250275

30 January 2024 in Liver International
Verified
Journal Article
Closed access
JYJiwon Yang
Jiwon Yang
JCJonggi Choi
Jonggi Choi
WCWon-Mook Choi
Won-Mook Choi
KKKang Mo Kim
Kang Mo Kim
HLHan Chu Lee
Han Chu Lee
JSJu Hyun Shim
Ju Hyun Shim

30 September 2024 in Journal of Liver Cancer
Verified
Journal Article
Open access
PDF file
JYJiwon Yang
Jiwon Yang
WCWon-Mook Choi
Won-Mook Choi
DLDanbi Lee
Danbi Lee
JSJu Hyun Shim
Ju Hyun Shim
KKKang Mo Kim
Kang Mo Kim
JCJonggi Choi
Jonggi Choi
Backgrounds/Aims: This study aimed to compare the outcomes of liver resection (LR) and transarterial chemoembolization (TACE) in patients with multinodular hepatocellular carcinoma (HCC) within the Milan criteria who were not eligible for liver transplantation.Methods: We retrospectively analyzed 483 patients with multinodular HCC within the Milan criteria, who underwent either LR or TACE as an initial therapy between 2013 and 2022. The overall survival (OS) in the entire population and recurrence-free survival (RFS) in patients who underwent LR and TACE and achieved a complete response were analyzed. Propensity score (PS) matching analysis was also used for a fair comparison of outcomes between the two groups.Results: Among the 483 patients, 107 (22.2%) and 376 (77.8%) underwent LR and TACE, respectively. The median size of the largest tumor was 2.0 cm, and 72.3% of the patients had two HCC lesions. The median OS and RFS were significantly longer in the LR group than in the TACE group (P<0.01 for both). In the multivariate analysis, TACE (adjusted hazard ratio [aHR], 1.81 and aHR, 2.41) and large tumor size (aHR, 1.43 and aHR, 1.44) were significantly associated with worse OS and RFS, respectively. The PS-matched analysis also demonstrated that the LR group had significantly longer OS and RFS than the TACE group (PS<0.05).Conclusions: In this study, LR showed better OS and RFS than TACE in patients with multinodular Barcelona Clinic Liver Cancer stage A HCC. Therefore, LR can be considered an effective treatment option for these patients.

29 January 2026 in Hepatology
Verified
Journal Article
Closed access
JYJiwon Yang
Jiwon Yang
YHYeongseok Hwang
Yeongseok Hwang
JJJin-Sung Ju
Jin-Sung Ju
SHSeungbong Han
Seungbong Han
JAJihyun An
Jihyun An
JSJu Hyun Shim
Ju Hyun Shim
Background and Aims: Type 2 diabetes mellitus (T2DM) is a recognized modifiable risk factor for HCC and liver-related mortality. The effects of newer antidiabetic agents—including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors—on hepatic outcomes remain uncertain. We aimed to evaluate whether these therapies reduce the risk of HCC and non-HCC liver-related events (LREs) in patients with T2DM. Approach and Results: A systematic literature search was performed to identify studies reporting hepatic complications among patients with T2DM prescribed GLP-1 RAs, SGLT-2 inhibitors, or DPP-4 inhibitors. Comparisons were made against patients receiving various glucose-lowering therapies other than the drug of interest. Subgroup analyses were conducted in patients with chronic liver disease. Random-effects meta-analyses were used to estimate pooled hazard ratios (HRs). Of 2,228 records screened, 36 cohort studies comprising 5,363,858 patients were included. Compared with other glucose-lowering therapies, GLP-1 RAs were associated with significantly reduced risks of HCC (pooled HR 0.77, 95% CI [0.66–0.90]) and LREs (0.79 [0.65–0.95]). SGLT-2 inhibitors similarly conferred protection against HCC (0.76 [0.67–0.86]) and LREs (0.82 [0.73–0.92]). By contrast, DPP-4 inhibitors were not associated with hepatoprotection, showing neutral effects on HCC (1.12 [0.91–1.39]) and increased risk of LREs (1.24 [1.15–1.34]). In patients with chronic liver disease, GLP-1 RAs were uniquely associated with reduced hepatic decompensation (0.79 [0.71–0.88]). Conclusions: GLP-1 RAs and SGLT-2 inhibitors were associated with hepatoprotective effects compared with other glucose-lowering therapies in patients with T2DM, with GLP-1 RAs showing additional benefits in chronic liver disease. These findings provide evidence on the relationships between antidiabetic drug classes and liver-related outcomes in patients with T2DM and may inform clinical decision-making.

1 August 2025 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
JYJiwon Yang
Jiwon Yang
JLJihye Lim
Jihye Lim
EKEun Hye Kim
Eun Hye Kim
JAJihyun An
Jihyun An
DLDanbi Lee
Danbi Lee
JSJu Hyun Shim
Ju Hyun Shim
Purpose: Transarterial chemoembolization (TACE) may cause gut dysbiosis by increasing portal vein pressure. However, its association with clinical outcomes remains unknown. We hypothesized that gut microbiota composition and diversity are associated with treatment response and prognosis in patients with hepatocellular carcinoma (HCC) undergoing TACE. Patients and Methods: This single-center, prospective cohort study included 96 adult HCC patients treated with TACE from April 2021 to November 2023. Fecal samples were collected before TACE (P0), one day (P1), and one month (P2) after TACE. Fecal 16S rRNA taxonomy was analyzed to evaluate microbial diversity, composition, and dynamic changes at each time point. The primary outcome was the association between the initial response to TACE and changes in microbial diversity and composition. Results: Out of the total participants, 63 (65.6%) were responders and 33 (34.4%) were non-responders. Responder stool samples had higher alpha-diversity than those of non-responders at baseline (median Shannon index: 4.26 vs 4.09), albeit not reaching statistical significance, and a higher abundance of short-chain fatty acid (SCFA)-producing bacteria at all time points. Alpha-diversity significantly decreased one day after TACE (P < 0.05 for P1 vs P0) and tended to recover one month later in the responders, albeit without statistical significance for P2 vs P0. Regarding beta-diversity, there were some changes in both responders and non-responders during the post-TACE period, albeit with different patterns. A low abundance of Roseburia cecicola (HR, 3.44; 95% CI, 1.10– 10.8) and Dialister_uc (HR, 3.90; 95% CI, 1.32– 11.6; both P < 0.05) at baseline was associated with worse overall survival. Conclusion: Specific SCFA-producing bacteria, such as Roseburia cecicola and Dialister_uc, were associated with treatment response and survival after TACE in patients with HCC, suggesting a potential prognostic role of the gut microbiome. Plain Language Summary: In this prospective study, the gut microbiomes of HCC patients who responded to TACE tended to have a higher baseline alpha-diversity than those of non-responders, with a significant difference in beta-diversity at baseline between the two groups.Alpha-diversity decreased immediately after TACE and tended to recover one month later, especially in patients achieving objective response who experienced relatively less prominent changes in beta-diversity.Initial responders had more abundant short-chain fatty acid (SCFA)-producing bacteria at baseline than those of the non-responder group. SCFA-producing bacterial species Roseburia cecicola and Dialister_uc were dominant in the baseline stool of the responder group, whose abundance was significantly associated with improved survival outcomes after treatment.Initial responders and non-responders to TACE for HCC showed different gut microbial dynamics. Our study suggests that gut microbial diversity and specific microbial components could serve as potential predictors of clinical outcomes and as targets for adjunctive probiotic or postbiotic strategies for such patients.

30 September 2025 in Journal of Liver Cancer
Verified
Journal Article
Open access
PDF file
JYJiwon Yang
Jiwon Yang
GKGunho Kim
Gunho Kim
JSJu Hyun Shim
Ju Hyun Shim
JAJihyun An
Jihyun An
Diabetes mellitus is a cardiometabolic risk factor associated with the development of various comorbidities and malignancies. It has a bidirectional relationship with chronic liver disease, promoting hepatic inflammation and fibrosis, which can ultimately progress to advanced liver diseases such as cirrhosis, hepatic decompensation, and hepatocellular carcinoma (HCC). Therefore, the importance of antidiabetic treatment has been increasingly emphasized as a strategy for preventing liver-related diseases in diabetic patients. Metformin, a first-line antidiabetic agent, has been shown to be effective in improving hepatic steatosis and preventing progression to advanced liver disease. Recently updated international guidelines recommend the use of metformin as a chemopreventive agent for HCC in diabetic patients, albeit with a weak recommendation. Meanwhile, as metformin alone is often insufficient for blood glucose control and concurrent metabolic comorbidities are increasingly prevalent, new second-line antidiabetic agents have been developed: glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, and dipeptidyl peptidase-4 inhibitors. These novel antidiabetic agents have demonstrated cardiovascular benefits, and protective effects on liver-related outcomes and mortality in previous studies. However, due to the limited number of studies and the variability in study populations, their effects remain inconsistent across different studies. Furthermore, there are no established therapeutic guidelines for diabetic patients with liver disease. Therefore, this review aims to examine the association between the use of novel second-line antidiabetic agents and the risk of liver-related outcomes and mortality in this population.